All Posts Tagged With: "GILD"
(ILMN) Two Major Biotech Trends In 2012
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood...
19Jan2012 | InvestmentU | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have taken place in the pharma sector over the last couple of years. With most...
9Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(JNJ) Spotlight on Hepatitis-C Market
Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies...
7Dec2011 | vitalstocks | 0 comments | Continued(GILD) Gilead’s Eviplera Drug is Cleared by European Medicines Agency
Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed...
30Nov2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts...
18Aug2011 | InvestmentU | 0 comments | Continued(GILD) Gilead Sciences Earnings Grow With HIV Franchise
Gilead Sciences Inc.’s (GILD) adjusted earnings per share of 95 cents for the second quarter of 2011 were 14 cents above the year-earlier earnings of 81 cents. The earnings growth was driven by a solid top-line performance in the reported quarter. Earnings were however a penny...
3Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Gets HIV Rights from Gilead
Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access...
14Jul2011 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences /Johnson & Johnson to Make HIV Combo Drug
Gilead Sciences, Inc.’s (GILD) strong HIV franchise received yet another shot in the arm with the announcement of a license agreement with Tibotec Pharmaceuticals, a division of Johnson & Johnson (JNJ), to develop and commercialize a new fixed dose combination HIV drug....
30Jun2011 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek
Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England Journal of Medicine. The trial results demonstrated that when patients suffering...
24Jun2011 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
14Jun2011 | vitalstocks | 0 comments | Continued(ABT) Abbott Labs First Quarter 2011 Earnings Preview
Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1%. Abbott Labs has surpassed earnings...
18Apr2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Earns European Clearance for Baraclude
Recently, Bristol-Myers Squibb Company (BMY) received a boost with the European Commission (EC) approving Baraclude (entecavir) for an additional indication. The current approval by the European regulatory authorities allows Bristol-Myers to market Baraclude in 27 nations of...
16Mar2011 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Refiles FDA New Drug Application for HIV Combo Pill
Gilead Sciences Inc. (GILD) recently refiled a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for the single-tablet combination of Truvada and TMC-278 (rilpivirine). The company is seeking to get the combination drug approved as a treatment of adult...
14Feb2011 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Terminates Letairis Phase III Trial
Gilead Sciences Inc.(GILD) recently announced that it will terminate its phase III trial (ARTEMIS-IPF) studying Letairis (ambrisentan) for the treatment of idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. The study’s Data Monitoring Committee (DMC) had conducted...
24Dec2010 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Earns FDA Label Expansion
Recently, Bristol-Myers Squibb Co. (BMY) received a boost with the US Food and Drug Administration (FDA) approving Baraclude (entecavir) for an additional indication. The current approval by the US regulatory authorities allows Bristol-Myers to market Baraclude for treating a...
17Nov2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Third Quarter 2010 Earnings Above Estimates on Antiviral Franchise
Gilead Sciences’ (GILD) third quarter 2010 earnings of $0.85 (excluding special items but including stock-based compensation expense) was a penny above the Zacks Consensus Estimate and well above the year-ago earnings of $0.74. The improved showing in the reported quarter was...
17Nov2010 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
15Nov2010 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Reports Wider Loss
Vertex Pharmaceuticals Inc. (VRTX) posted a higher third-quarter loss (including stock-based compensation expense) of 99 cents per share, compared with the Zacks Consensus Estimate of a loss of 91 cents and the year-ago loss of 83 cents. Increased expenses related to the potential...
29Oct2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Files Marketing Authorization Application for HIV Drug
Gilead Sciences Inc. (GILD) recently announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for its once daily, single tablet, fixed dose combination of Truvada and TMC278 (rilpivirine) as a HIV treatment...
8Sep2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Neutral Rating Due To Generic Risk For Hepsera
Gilead Sciences Inc. (GILD) recently announced that Sigmapharm Laboratories, LLC is seeking to manufacture and market a generic version of Gilead’s hepatitis B (HBV) treatment, Hepsera. Sigmapharm Labs submitted an Abbreviated New Drug Application (ANDA) with the US Food...
22Aug2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
26Jul2010 | vitalstocks | 0 comments | Continued(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
20Jul2010 | vitalstocks | 0 comments | Continued(UTHR) United Therapeutics Beats Expectations on Strong Revenues
United Therapeutics Corp. (UTHR) reported first-quarter profit of 32 cents per share, a couple of cents above the Zacks Consensus Estimate and 28% above the year-ago earnings of 25 cents. A huge boost in revenues helped drive earnings despite an increase in operating expenses. Revenues...
6May2010 | vitalstocks | 0 comments | Continued(ABT) Pharma & Biotech Stock Review – April 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant...
29Apr2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Beats The Street but Lowers Outlook
Gilead Sciences (GILD) reported strong first quarter fiscal 2010 results with revenues increasing 36% year-over-year to $2.09 billion. The company’s earnings per share (EPS) came in at 92 cents. However, excluding non- recurring items and treating stock-based compensation as...
21Apr2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Earnings Preview – Fourth Quarter Highlights
Gilead Sciences (GILD) is scheduled to release its first quarter 2010 earnings on Apr 20, 2010. The company is expected to earn 96 cents during the quarter, according to the Zacks Consensus Estimate. Fourth quarter highlights Gilead reported revenue of $2.03 billion, up 42%,...
14Apr2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Initiates Late-Stage Trial
Recently, Gilead Sciences (GILD) initiated the phase III program of Quad, which is a fixed dose combination of four drugs: elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The phase III program consists of two trials (Studies 102 and 103), which will...
13Apr2010 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Shows Uptrend in Earnings Estimates
Earnings estimates for Gilead Sciences (GILD) are on the rise following the release of strong fourth quarter and full year 2009 results. The company’s earnings per share (EPS) came in at 90 cents, well above the Zacks Consensus Estimate of 82 cents and the year ago quarter’s...
5Mar2010 | vitalstocks | 0 comments | Continued